In 2023, Croatia leads in antiarrhythmic medicine sales per capita at $8.1, despite a -0.49% YoY decline. South Korea showed the highest YoY growth at 17.61%, while Sweden experienced the most significant decrease at -12.94%. Over the past five years, noteworthy growth trends can be observed in countries like South Korea and the Czech Republic, indicating an increasing demand. Meanwhile, declines in other markets like Belgium and Spain suggest fluctuating healthcare priorities and economic factors.
Future trends to watch include the impact of technological advancements in cardiac treatments, regional healthcare policy changes, and demographic shifts. The expanding aging population could drive increased demand for antiarrhythmic medicines, especially in countries with current low per capita sales.
Top countries in Antiarrhythmic Medicine Sales by Country
# | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
---|---|---|---|---|---|---|
1 | 1 Croatia | 8.1 | 2023 | 0% | -0.49% | View data |
2 | 2 Belgium | 1.6 | 2023 | 0% | -1.21% | View data |
3 | 3 Czech Republic | 1.6 | 2023 | 0% | +1.3% | View data |
4 | 4 South Korea | 0.9 | 2023 | +12.5% | +17.61% | View data |
5 | 5 Austria | 0.9 | 2023 | 0% | 0% | View data |
6 | 6 Finland | 0.9 | 2023 | 0% | 0% | View data |
7 | 7 Ireland | 0.8 | 2023 | 0% | 0% | View data |
8 | 8 Spain | 0.8 | 2023 | 0% | -4.36% | View data |
9 | 9 Canada | 0.5 | 2023 | 0% | -3.58% | View data |
10 | 10 Sweden | 0.5 | 2023 | -16.67% | -12.94% | View data |